Noticias de CELC_US
Noticias del mercado
Últimas noticias sobre CELC_US — 208 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Celcuity falls after detailed late-stage trial data for breast cancer drug
Celcuity falls after detailed late-stage trial data for breast cancer drug
Celcuity shares fall despite strong phase 3 breast cancer trial data (CELC)
CELC Maintained by Wells Fargo -- Price Target Lowered to $166
CELC Maintained by Wells Fargo -- Price Target Lowered to $166
Celcuity announces $400M convertible notes offering
Celcuity announces $400M convertible notes offering
Guggenheim reiterates Celcuity stock rating on phase 3 trial data By Investing.com
Guggenheim reiterates Celcuity stock rating on phase 3 trial data By Investing.com
Celcuity Plans $400 Million Convertible Notes Offering
H.C. Wainwright cuts Celcuity stock price target on revised penetration estimates By Investing.com
H.C. Wainwright cuts Celcuity stock price target on revised penetration estimates
Celcuity proposes $400 million convertible notes offering By Investing.com
Celcuity proposes $400 million convertible notes offering By Investing.com
Celcuity proposes $400 million convertible notes offering By Investing.com
MINNEAPOLIS, 3 de junio de 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (
MINNEAPOLIS, 03 de junio de 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” o la “Compañía”), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias dirigidas para el tratamiento de
Página 4 de 11
